New hope for tough bone cancers: adding old drug to chemo
NCT ID NCT03598595
Summary
This study is testing whether adding the drug hydroxychloroquine to standard chemotherapy (gemcitabine and docetaxel) helps control recurrent osteosarcoma, a type of bone cancer that has returned or stopped responding to treatment. It aims to find the safest dose and see if this three-drug combination can stop cancer growth better than chemotherapy alone. The trial is for patients whose cancer has come back after initial treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.